QIAGEN N.V.
No enriched coverage for $QGEN in the last 7 days.
No SEC Form 4 filings for $QGEN in the last 30 days.
M&T Bank Corp recently acquired a new stake in Qiagen N.V., purchasing 48,152 shares valued at approximately $2.19 million during the fourth quarter. This move comes as Qiagen's shares have been trading near their 52-week low, despite the company meeting analyst expectations for its quarterly earnings per share. Analysts currently rate Qiagen as a "Moderate Buy" with an average price target of $46.38.
Qiagen NV (QGEN) shares recently dropped 10.7% and are currently trading at $34.02, significantly below its GF Value™ estimate of $53.19, leading to its classification as undervalued by GuruFocus. Despite an above-average GF Score™ of 79/100, indicating strong financial health and valuation, its growth and momentum ranks are moderate. There have been no insider transactions in the last three months, suggesting stable but cautious insider sentiment.
QIAGEN N.V. (NYSE: QGEN) has launched its QIAstat-Dx BCID GPF Plus AMR Panel for bloodstream infection testing, a CE-IVDR-certified panel that identifies 20 gram-positive bacterial and fungal pathogens and 10 antimicrobial resistance markers. This expansion moves QIAGEN's QIAstat-Dx portfolio into bloodstream infection applications, building on its existing respiratory, gastrointestinal, and meningitis testing. The company announced the product launch at the ESCMID Global 2026 Congress and plans to develop additional panels for gram-negative pathogens.
